Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 21 clinical trials
Eribulin in Advanced Solitary Fibrous Tumor (ERASING)

Phase II study on advanced Solitary Fibrous Tumor (SFT) treated with eribulin

  • 6 views
  • 14 Feb, 2022
  • 2 locations
Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

This is a multicenter, phase II, open-label, single-arm investigator initiated trial to evaluate the efficacy and safety of eribulin mesylate combined with anlotinib in metastatic HER2 negative

  • 3 views
  • 29 May, 2021
  • 1 location
Phase I of Eribulin and Oral Irinotecan for Relapsed or Refractory Solid Tumors

This Phase I trial will establish the recommended phase II dose of eribulin in combination with fixed doses of oral irinotecan in adolescents and young adults with relapsed or refractory solid

  • 2 views
  • 08 Nov, 2020
  • 1 location
Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

To evaluate the efficacy of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer.

  • 0 views
  • 17 Jun, 2022
  • 1 location
  • 0 views
  • 15 Sep, 2022
  • 1 location
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of

vinorelbine
estrogen
trastuzumab
carcinoma
mammogram
  • 0 views
  • 14 Jul, 2022
  • 94 locations
Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)

After progression of disease after one chemotherapy, metastatic breast cancer patients will be randomized 1:1 to one of the following treatment arms: Arm A. Eribulin Arm B. Paclitaxel

EGFR
advanced breast cancer
paclitaxel
growth factor
HER2
  • 0 views
  • 15 Jul, 2022
  • 2 locations
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin

neutrophil count
cancer
systemic therapy
angiosarcoma
tumor cells
  • 122 views
  • 25 Mar, 2022
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

This phase Ib/II trial tests the safety and side effects of grapiprant and eribulin and whether they work to shrink tumors in patients with inflammatory breast cancer that has spread to other

  • 0 views
  • 10 Jul, 2022
  • 1 location
Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

This phase II trial studies how well atezolizumab, cobimetinib, and eribulin work in treating patients with inflammatory breast cancer that has spread to other places in the body (metastatic

cancer
ejection fraction
breast cancer
neoadjuvant therapy
absolute neutrophil count
  • 1 views
  • 31 Jan, 2022
  • 1 location